I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.
<h4>Background</h4>Resistance of pandemic A(H1N1)2009 (H1N1pdm09) virus to neuraminidase inhibitors (NAIs) has remained limited. A new mutation I223R in the neuraminidase (NA) of H1N1pdm09 virus has been reported along with H275Y in immunocompromised patients. The aim of this study was t...
Guardado en:
Autores principales: | Jérome LeGoff, Dominique Rousset, Georges Abou-Jaoudé, Anne Scemla, Patricia Ribaud, Séverine Mercier-Delarue, Valérie Caro, Vincent Enouf, François Simon, Jean-Michel Molina, Sylvie van der Werf |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1dce460bbae34f74815b5172a879457e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.
por: Marie-Anne Rameix-Welti, et al.
Publicado: (2008) -
Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.
por: Jeff Butler, et al.
Publicado: (2014) -
Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus
por: Kyeonghye Guk, et al.
Publicado: (2020) -
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
por: Xavier Duval, et al.
Publicado: (2010) -
Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies
por: Jin Gao, et al.
Publicado: (2019)